Amicus Therapeutics, Inc. (FOLD) Expected to Post Earnings of -$0.35 Per Share

Equities research analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings per share of ($0.35) for the current quarter, Zacks reports. Four analysts have made estimates for Amicus Therapeutics’ earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.38). Amicus Therapeutics reported earnings of ($0.33) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 6.1%. The business is scheduled to report its next quarterly earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Amicus Therapeutics will report full-year earnings of ($1.39) per share for the current fiscal year, with EPS estimates ranging from ($1.61) to ($1.13). For the next year, analysts anticipate that the firm will post earnings of ($0.96) per share, with EPS estimates ranging from ($1.36) to ($0.61). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.09). Amicus Therapeutics had a negative return on equity of 64.11% and a negative net margin of 386.18%. The firm had revenue of $34.00 million for the quarter, compared to the consensus estimate of $37.82 million. The firm’s quarterly revenue was up 103.6% compared to the same quarter last year.

FOLD has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price target on shares of Amicus Therapeutics in a research report on Tuesday, February 5th. Citigroup raised shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $12.59 price target on the stock in a research report on Wednesday, January 16th. Robert W. Baird set a $20.00 price target on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 22nd. Janney Montgomery Scott initiated coverage on shares of Amicus Therapeutics in a research report on Friday, April 5th. They set a “buy” rating and a $13.91 price target on the stock. Finally, ValuEngine raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $18.19.

In other Amicus Therapeutics news, insider Jay Barth sold 70,000 shares of the company’s stock in a transaction on Monday, February 25th. The shares were sold at an average price of $12.52, for a total value of $876,400.00. Following the transaction, the insider now directly owns 156,037 shares in the company, valued at $1,953,583.24. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO John F. Crowley sold 20,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $13.60, for a total transaction of $272,000.00. Following the completion of the transaction, the chief executive officer now owns 678,844 shares in the company, valued at $9,232,278.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 180,000 shares of company stock worth $2,401,200. Corporate insiders own 2.90% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Bank of Montreal Can grew its stake in shares of Amicus Therapeutics by 117.9% in the fourth quarter. Bank of Montreal Can now owns 3,428 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,855 shares in the last quarter. Sageworth Trust Co acquired a new position in shares of Amicus Therapeutics in the first quarter valued at about $34,000. Strs Ohio grew its stake in shares of Amicus Therapeutics by 56.0% in the fourth quarter. Strs Ohio now owns 3,900 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,400 shares in the last quarter. US Bancorp DE grew its stake in shares of Amicus Therapeutics by 365.6% in the first quarter. US Bancorp DE now owns 3,245 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 2,548 shares in the last quarter. Finally, Sage Capital Advisors llc grew its stake in shares of Amicus Therapeutics by 13.8% in the fourth quarter. Sage Capital Advisors llc now owns 12,400 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 1,500 shares in the last quarter.

NASDAQ FOLD traded up $0.30 on Wednesday, hitting $12.65. 59,981 shares of the stock were exchanged, compared to its average volume of 2,569,449. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.45. Amicus Therapeutics has a 52 week low of $8.27 and a 52 week high of $17.62. The firm has a market capitalization of $2.86 billion, a P/E ratio of -9.47 and a beta of 1.79.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Featured Article: Fundamental Analysis – How It Helps Investors

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.